2009/03/26    Dr. Ying Luo will give a keynote speech at the 2009 & 8th Annual China Pharma, Life Science & Healthcare Industry Summit Week (CPHIS 2009) in Shanghai.

2009/02/10    Dr. Ying Luo, Chairman of Shanghai Genomics and CEO of GNI, chaired the IBC Life Sciences Conference: Access India & China. He also presented the drug co-development model of Shanghai Genomics at the conference.

2009/01/21    The leading drug candidate F647 demonstrated good results in Phase II trial for Radiation Pneumonitis. In 2008, Shanghai Genomics has completed Phase II trial of F647 for Idiopathic Pulmonary Fibrosis. The Company will prepare for Phase III trial of F647 for Radiation Pneumonitis in the second half of 2009. NDA filing is also be prepared for Idiopathic Pulmonary Fibrosis. Dr. Ying Luo said, "Completion of another Phase II trial of F647 proved that Shanghai Genomics is a leading biotech company in China. With the progress of Phase I trial of F351 for liver fibrosis, Shanghai Genomics will build a rich novel drug pipeline in China."

 
© 2008 shanghaigenomics.com. All rights reserved. Shanghai ICP 05006045